ConductScience.org, home

Paper40544243

Edaravone-Dexborneol slows down pathological progression and cognitive decline via inhibiting S100A9 in APPswe/PS1dE9 mice.

Mao R and 11 others. Alzheimers Res Ther, 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Edaravone-Dexborneol slows down pathological progression and cognitive decline via inhibiting S100A9 in APPswe/PS1dE9 mice. Papers, record 40544243. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40544243

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Edaravone-Dexborneol slows down pathological progression and cognitive decline via inhibiting S100A9 in APPswe/PS1dE9 mice.
PubMed
Journal
Alzheimers Res Ther
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-05-14
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mao RRui
2Shu SShu
3Sun MMin
4Chen JJiang
5Hu MMengsha
6Ye LLei
7Xu SSiyi
8Jia JJunqiu
9Shao WWenxuan
10Bao XXinyu
11Xu YYun
12Zhu XXiaolei

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Calgranulin BMajor topic
Cognitive DysfunctionMajor topic
EdaravoneMajor topic
Alzheimer DiseaseMajor topic
Animals
Mice
Male
Mice, Transgenic
Disease Progression
Hippocampus
Disease Models, Animal
Oxidative Stress

Source PubMed

Download CSV of topics

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
82271480the National Natural Science Foundation of ChinaPubMed
82471460the National Natural Science Foundation of ChinaPubMed
BK20230053the Natural Science Foundation of Jiangsu Province of ChinaPubMed
BK20231120the Natural Science Foundation of Jiangsu Province of ChinaPubMed
2022ZD0211800the STI2030-Major ProjectsPubMed
ZKX22025Nanjing Medical Science and Technology Development FoundationPubMed

Source PubMed

Download CSV of grants

References68

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138040838Colon-targeted S100A8/A9-specific peptide systems ameliorate colitis and colitis-associated colorectal cancer in mouse models.Acta Pharmacol Sin2024https://conductscience.org/library/papers/38040838PubMed
237496671QHRD106 ameliorates ischemic stroke injury as a long-acting tissue kallikrein preparation.iScience2023https://conductscience.org/library/papers/37496671PubMed
312529407Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro.Mol Cell Biol2003https://conductscience.org/library/papers/12529407PubMed
424586443S100A9 knockout decreases the memory impairment and neuropathology in crossbreed mice of Tg2576 and S100A9 knockout mice model.PLoS One2014https://conductscience.org/library/papers/24586443PubMed
538403918S100A8-enriched microglia populate the brain of tau-seeded and accelerated aging mice.Aging Cell2024https://conductscience.org/library/papers/38403918PubMed
633950214PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA.Nucleic Acids Res2021https://conductscience.org/library/papers/33950214PubMed
724240735The role of pro-inflammatory S100A9 in Alzheimer's disease amyloid-neuroinflammatory cascade.Acta Neuropathol2014https://conductscience.org/library/papers/24240735PubMed
825969431Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis.Ann Rheum Dis2015https://conductscience.org/library/papers/25969431PubMed
928687052Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood-brain barrier permeability.Drug Deliv2017https://conductscience.org/library/papers/28687052PubMed
1034888686Neuroprotective effects of synthetic borneol and natural borneol based on the neurovascular unit against cerebral ischaemic injury.J Pharm Pharmacol2022https://conductscience.org/library/papers/34888686PubMed
111789684Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.Ann Neurol1991https://conductscience.org/library/papers/1789684PubMed
1229653606NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.Alzheimers Dement2018https://conductscience.org/library/papers/29653606PubMed
1319440546Amyloid formation by the pro-inflammatory S100A8/A9 proteins in the ageing prostate.PLoS One2009https://conductscience.org/library/papers/19440546PubMed
1433979140Natural Compound from Olive Oil Inhibits S100A9 Amyloid Formation and Cytotoxicity: Implications for Preventing Alzheimer's Disease.ACS Chem Neurosci2021https://conductscience.org/library/papers/33979140PubMed
1522457725MRP14 (S100A9) protein interacts with Alzheimer beta-amyloid peptide and induces its fibrillization.PLoS One2012https://conductscience.org/library/papers/22457725PubMed
1612640137Myeloid cell function in MRP-14 (S100A9) null mice.Mol Cell Biol2003https://conductscience.org/library/papers/12640137PubMed
1725907296S100A9 promotes human hepatocellular carcinoma cell growth and invasion through RAGE-mediated ERK1/2 and p38 MAPK pathways.Exp Cell Res2015https://conductscience.org/library/papers/25907296PubMed
1833913042Borneol: a Promising Monoterpenoid in Enhancing Drug Delivery Across Various Physiological Barriers.AAPS PharmSciTech2021https://conductscience.org/library/papers/33913042PubMed
1935470467Edaravone dexborneol protects cerebral ischemia reperfusion injury through activating Nrf2/HO-1 signaling pathway in mice.Fundam Clin Pharmacol2022https://conductscience.org/library/papers/35470467PubMed
2034289882The informed road map to prevention of Alzheimer Disease: A call to arms.Mol Neurodegener2021https://conductscience.org/library/papers/34289882PubMed

See all 68 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
42039150Monoclonal antibodies and small molecules: on the cutting edge of Alzheimer's disease therapy.Front Cell Dev Biol2026https://conductscience.org/library/papers/42039150

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40544243

GET https://conductscience.org/api/papers/v1/40544243/references?page=2